Georgia's Online Cancer Information Center

Find A Clinical Trial

Trametinib in Treating Patients with Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Cancer Type
Cancer-Related Syndrome
Hematopoietic Malignancies
Unknown Primary
Trial Phase
Phase II
1 Months - 21 Years, Male and Female
Study Type
Protocol IDs
ADVL1521 (primary)
Study Sponsor
Children's Oncology Group


This phase II trial studies how well trametinib works in treating patients with juvenile myelomonocytic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.


I. To determine the objective response rate to trametinib in children with recurrent or refractory juvenile myelomonocytic leukemia (JMML).

I. To further define and describe the toxicities of single agent trametinib in children with recurrent or refractory JMML.
II. To further characterize the pharmacokinetics of trametinib in children with recurrent or refractory JMML.
III. To prospectively evaluate mutant allele burden as a marker of disease activity in JMML.
IV. To measure the rate of complete responses in children with recurrent or refractory JMML.
V. To measure the duration of response among responders.

I. To describe the distribution of JMML diagnostic criteria in children with recurrent or refractory JMML.

Patients receive trametinib orally (PO) once daily (QD) on days 1-28. Treatment repeats every 28 days for up to 12 cycles in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up annually for up to 5 years.


  1. Patients must have had histologic verification of juvenile myelomonocytic leukemia (JMML) at original diagnosis and currently have relapsed or refractory disease; the diagnosis is made based on the following criteria * JMML category 1 (all of the following): the diagnostic criteria must include all features in category 1 and EITHER (i) one of the features in category 2 OR (ii) two features from category 3 to make the diagnosis ** Splenomegaly ** > 1000 (1 x 10^9/uL) circulating monocytes ** < 20% blasts in the bone marrow or peripheral blood ** Absence of the t(9;22) or BCR/ABL fusion gene * JMML category 2 (at least one of the following if at least two category 3 criteria are not present): ** Somatic mutation in RAS or PTPN11 ** Clinical diagnosis of NF1 or NF1 gene mutation ** Homozygous mutation in CBL ** Monosomy 7 * JMML category 3 (at least two of the following if no category 2 criteria are met): ** Circulating myeloid precursors ** White blood cell count, > 10 000 (10 x 10^9/ uL) ** Increased hemoglobin F for age ** Clonal cytogenetic abnormality ** GM-CSF hypersensitivity
  2. Patients with refractory or relapsed JMML must have had at least one cycle of intensive frontline therapy or at least 2 cycles of a deoxyribonucleic acid (DNA) demethylating agent with persistence of disease, defined by clinical symptoms or the presence of a clonal abnormality; frontline therapy is defined as one cycle of intravenous chemotherapy that includes of any of the following agents: fludarabine, cytarabine, or any anthracycline but specifically excludes oral 6-mercaptopurine; frontline therapy will also include any conditioning regimen as part of a stem cell transplant; patients who transform to AML at any point with more than 20% blasts are not eligible for this trial
  3. Patients must have a Lansky or Karnofsky performance status score of >= 50, corresponding to Eastern Cooperative Oncology Group (ECOG) categories 0, 1 or 2; use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age; patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score
  4. Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to study enrollment * Myelosuppressive chemotherapy: patients must have completely recovered from all acute toxic effects of chemotherapy, immunotherapy or radiotherapy prior to study enrollment; at least 14 days must have elapsed since the completion of cytotoxic therapy, with the exception of hydroxyurea ** Note: cytoreduction with hydroxyurea can be initiated and continued for up to 24 hours prior to the start of protocol therapy * Hematopoietic growth factors: at least 14 days after the last dose of a long-acting growth factor (e.g., pegfilgrastim) or 7 days for short-acting growth factor; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur * Biologic (anti-neoplastic agent): at least 7 days must have elapsed since completion of therapy with a biologic agent; for agents that have known adverse events occurring beyond 7 days after administration, this period prior to enrollment must be extended beyond the time during which adverse events are known to occur * Monoclonal antibodies: ** At least 30 days after the completion of any type of immunotherapy, e.g. tumor vaccines ** At least 3 half-lives must have elapsed since prior therapy that included a monoclonal antibody * Radiotherapy: ** >= 2 weeks must have elapsed since local palliative external radiation therapy (XRT) (small port) ** >= 6 months must have elapsed if prior craniospinal XRT was received, if >= 50% of the pelvis was irradiated, or if traumatic brain injury (TBI) was received ** >= 4 weeks must have elapsed if other substantial bone marrow irradiation was given * Stem cell transplant or rescue without TBI: no evidence of active graft versus (vs.) host disease and >= 3 months must have elapsed since transplant; >= 4 weeks must have elapsed since any donor lymphocyte infusion
  5. Patients must not be known to be refractory to red blood cell or platelet transfusions
  6. Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 or a serum creatinine based on age/gender as follows: * Age: Maximum serum creatinine (mg/dL) ** 1 month to < 6 months: 0.4 (male) 0.4 (female) ** 6 months to < 1 year: 0.5 (male) 0.5 (female) ** 1 to < 2 years: 0.6 (male) 0.6 (female) ** 2 to < 6 years: 0.8 (male) 0.8 (female) ** 6 to < 10 years: 1 (male) 1 (female) ** 10 to < 13 years: 1.2 (male) 1.2 (female) ** 13 to < 16 years: 1.5 (male) 1.4 (female) ** >= 16 years: 1.7 (male) 1.4 (female)
  7. Total bilirubin =< 1.5 x upper limit of normal (ULN) for age
  8. Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 3 x ULN (=< 135 U/L) (for the purpose of this study, the ULN for SGPT is 45 U/L)
  9. Serum albumin >= 2 g/dL
  10. Shortening fraction of >= 27% by echocardiogram OR ejection fraction of >= 50% by multi-gated acquisition (MUGA)
  11. Corrected QT (by Bazett's formula [QTcB]) interval < 450 msecs
  12. Patients must be able to swallow tablets or liquid; use of a nasogastric or gastrostomy (G) tube is also allowed

Treatment Sites in Georgia

Aflac Cancer and Blood Disorders Center of Children’s at Egleston

1405 Clifton Road NE
3rd Floor
Atlanta, GA 30322

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Georgia CORE


Advancing Cancer Care through Partnerships and Innovation

Georgia CORE is a statewide nonprofit that leverages partnerships and innovation to attract more clinical trials, increase research, and promote education and early detection to improve cancer care for Georgians in rural, urban, and suburban communities across the state.